サンプル依頼リスト カート
  • English
市場調査レポート
商品コード
1226796

中南米の過活動膀胱治療市場の2028年までの予測-地域別分析-薬物療法別、疾患タイプ別

South & Central America Overactive Bladder Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Pharmacotherapy and Disease Type
出版日: | 発行: The Insight Partners | ページ情報: 英文 124 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
中南米の過活動膀胱治療市場の2028年までの予測-地域別分析-薬物療法別、疾患タイプ別
出版日: 2023年01月25日
発行: The Insight Partners
ページ情報: 英文 124 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

中南米の過活動膀胱治療市場は、2022年の4億7,249万米ドルから2028年には5億4,353万米ドルに成長すると予測され、2022年から2028年までのCAGRは2.4％と推定されています。

M&Aの増加が中南米の過活動膀胱治療市場の成長を促進する

企業はM&Aを通じて、新市場への参入や新技術の獲得により競争力を高めることができます。過活動膀胱治療市場で進行中のM&Aは、さまざまな企業に成長機会をもたらしています。2021年7月、ウロメディカルは、過活動膀胱の治療に特化したワイヤレス給電、注射可能なマイクロテクノロジー神経刺激装置を提供するマイクロンメディカルを買収し、泌尿器科のポートフォリオを強化しました。患者の日常生活に簡単に取り入れることができるこれらの神経刺激装置は、便利で安全、低侵襲で費用対効果の高い泌尿器科治療の選択肢を提供します。2021年2月、医療技術会社であるAxonics Modulation Technologies, Inc.は、Contura Ltd.とその独自製品であるストレス性尿失禁（SUI）女性用尿道増量剤Bulkamidを獲得しました。アクソニックスは、排尿・排便障害治療用の新しい埋め込み型仙骨神経調節（SNM）デバイスを製造・販売しています。Contura Ltd.の買収は、SNM事業を世界的に拡大し、非常に未開拓な大規模なSUI市場に対応する機会を提供するものです。同社は、泌尿器科医や泌尿器科医が患者を治療するために、臨床的に差別化された失禁ソリューション一式を提供することを計画しています。このように、合併・買収の増加が中南米の過活動膀胱治療市場の成長を後押ししています。

中南米の過活動膀胱治療市場の概要

中南米の過活動膀胱治療市場は、ブラジル、アルゼンチン、その他南米に分類されます。ブラジルは同地域で最大の市場シェアを占め、予測期間中に最も高いCAGRを記録すると予測されています。市場成長の背景には、老年人口の増加や慢性疾患の有病率の上昇があります。同地域では、過活動膀胱症候群の原因となる肥満、不健康な生活パターン、その他のリスクの高い有病率が示されています。その結果、同地域では過活動膀胱治療に対する意識が高まっており、同地域の市場成長に影響を及ぼしています。

中南米の過活動膀胱治療市場の収益と2028年までの予測（US$Million）

中南米の過活動膀胱治療市場のセグメンテーション

中南米の過活動膀胱治療市場は、薬物療法、疾患タイプ、国別に細分化されています。

薬物療法に基づき、中南米の過活動膀胱治療市場は、抗コリン薬、ミラベグロン、ボトックス、神経刺激、膀胱内注入に区分されます。2022年にはミラベグロンセグメントが最大シェアを記録しました。

疾患タイプに基づき、中南米の過活動膀胱治療市場は特発性過活動膀胱と神経原性膀胱に二分されます。2022年の市場では、特発性過活動膀胱分野がより大きなシェアを占めています。

国別に見ると、中南米の過活動膀胱治療市場は、ブラジル、アルゼンチン、その他中南米に区分されます。2022年にはブラジルが市場を独占しました。

目次

第1章 イントロダクション

第2章 中南米の過活動膀胱治療市場-主要な要点

第3章 調査手法

  • カバレッジ
  • 2次調査
  • 1次調査

第4章 過活動膀胱治療市場- 市場情勢

  • 南米のPEST分析
  • 専門家別オピニオン

第5章 中南米の過活動膀胱治療市場-主要市場力学

  • 市場促進要因
    • 尿失禁の有病率の増加
    • 尿路感染症の発生率の増加
  • 主な市場抑制要因
    • 治療薬のリコール
  • 主な市場機会
    • M&A（合併・買収）の増加
  • 今後の動向
    • 強力な医薬品パイプラインと新規治療薬の相次ぐ上市
  • 影響度分析

第6章 中南米の過活動膀胱治療市場-SAM分析

  • 中南米の過活動膀胱治療市場収益と予測・分析

第7章 中南米の過活動膀胱治療市場分析・2028年予測：薬物療法別

  • 中南米の過活動膀胱治療市場：薬物療法別2021年・2028年（%）
  • ミラベグロン
  • ボトックス
  • 神経刺激療法
  • 抗コリン薬
  • 膀胱内注入

第8章 中南米の過活動膀胱治療薬市場の分析と2028年までの予測：疾患タイプ別

  • 中南米の過活動膀胱治療市場：疾患タイプ別2021年・2028年（%）
  • 特発性過活動膀胱
  • 神経原性過活動膀胱

第9章 過活動膀胱治療市場の収益と2028年までの予測：国別分析

  • 中南米の過活動膀胱治療市場：国別2021年・2028年（%）
    • ブラジル
    • アルゼンチン
    • その他

第10章 過活動膀胱治療市場-業界情勢

  • 有機的開発

第11章 企業プロファイル

  • Astellas Pharma Inc
  • AbbVie Inc
  • Teva Pharmaceutical Industries Ltd
  • Endo Pharmaceuticals Inc.
  • Hisamitsu Pharmaceutical Co., Inc.
  • Medtronic Plc
  • Pfizer Inc

第12章 付録

図表

List Of Tables

  • Table 1. Brazil Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
  • Table 2. Brazil Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. Brazil Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. Brazil Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
  • Table 5. Argentina Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
  • Table 6. Argentina Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. Argentina Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. Argentina Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
  • Table 9. Rest of SAM Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
  • Table 10. Rest of SAM Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. Rest of SAM Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Rest of SAM Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
  • Table 13. Organic Developments Done by Companies
  • Table 14. Glossary of Terms

List Of Figures

  • Figure 1. SAM Overactive Bladder Treatment Market Segmentation
  • Figure 2. SAM Overactive Bladder Treatment Market Segmentation, By Country
  • Figure 3. SAM Overactive Bladder Treatment Market Overview
  • Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in SAM Overactive Bladder Treatment market
  • Figure 5. Argentina Is Expected to Show Remarkable Growth During the Forecast Period
  • Figure 7. SAM: PEST Analysis
  • Figure 8. SAM Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
  • Figure 9. SAM Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
  • Figure 10. SAM Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
  • Figure 11. Mirabegron: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 12. Botox: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 13. Neurostimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 14. Transcutaneous Sacral Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 15. Transcutaneous Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
  • Figure 16. Percutaneous Posterior Tibial Nerve: SAM Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 17. Others: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
  • Figure 18. Anticholinergics: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 19. Solifenacin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 20. Oxybutynin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 21. Fesoterodine: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 22. Darifenacin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
  • Figure 23. Tolterodine: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 24. Trospium: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 25. Other Anticholinergics: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
  • Figure 26. Intravesical Instillation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 27. SAM Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
  • Figure 28. Idiopathic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 29. Neurogenic: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
  • Figure 30. SAM: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (USD Million)
  • Figure 31. Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
  • Figure 32. Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
  • Figure 33. Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
目次
Product Code: BMIRE00027968

The South & Central America overactive bladder treatment market is expected to grow from US$ 472.49 million in 2022 to US$ 543.53 million by 2028; it is estimated to grow at a CAGR of 2.4% from 2022 to 2028.

Increasing Number of Mergers and Acquisitions is Propelling South & Central America Overactive Bladder Treatment Market Growth

Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021, Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients' daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.-a medical technology company-acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling South & Central America overactive bladder treatment market growth

South & Central America Overactive Bladder Treatment Market Overview

The South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to account for the largest share of the market in the region, and it is projected to register the highest CAGR during the forecast period. The market growth is attributed to the growing geriatric population and rising prevalence of chronic disorders. The region is witnessing the high prevalence of obesity, unhealthy lifestyle patterns, and other risks, which are contributing to overactive bladder syndrome. As a result, the awareness of overactive bladder treatment has increased across the region, which is influencing the market growth in the region.

South & Central America Overactive Bladder Treatment Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Overactive Bladder Treatment Market Segmentation

The South & Central America overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.

Based on pharmacotherapy, the South & Central America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.

Based on disease type, the South & Central America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.

Based on country, the South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.

AbbVie Inc; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the South & Central America overactive bladder treatment market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the South & Central America overactive bladder treatment market
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America overactive bladder treatment market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the overactive bladder treatment market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

Table Of Contents

1. Introduction

  • 1.1 Study Scope
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 SAM Overactive Bladder Treatment Market- By Pharmacotherapy
    • 1.3.2 SAM Overactive Bladder Treatment Market- By Disease Type
    • 1.3.3 SAM Overactive Bladder Treatment Market - By Country

2. SAM Overactive Bladder Treatment Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. SAM Overactive Bladder Treatment Market - Market Landscape

  • 4.1 Overview
  • 4.2 SAM PEST Analysis
  • 4.3 Expert Opinion

5. SAM Overactive Bladder Treatment Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Increase in Prevalence of Urinary Incontinence
    • 5.1.2 Growing Incidence of Urinary Tract Infections
  • 5.2 Key Market Restraints
    • 5.2.1 Recalls of Therapeutic Drugs
  • 5.3 Key Market Opportunities
    • 5.3.1 Increasing Number of Mergers and Acquisitions
  • 5.4 Future Trends
    • 5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
  • 5.5 Impact analysis

6. SAM Overactive Bladder Treatment Market - SAM Analysis

  • 6.1 SAM Overactive Bladder Treatment Market Revenue Forecast and Analysis

7. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy

  • 7.1 Overview
  • 7.2 SAM Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
  • 7.3 Mirabegron
    • 7.3.1 Overview
    • 7.3.2 Mirabegron: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Botox
    • 7.4.1 Overview
    • 7.4.2 Botox: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Neurostimulation
    • 7.5.1 Overview
    • 7.5.2 Neurostimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.3 Transcutaneous Sacral Nerve Stimulation
      • 7.5.3.1 Overview
      • 7.5.3.2 Transcutaneous Sacral Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.4 Transcutaneous Tibial Nerve Stimulation
      • 7.5.4.1 Overview
      • 7.5.4.2 Transcutaneous Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
      • 7.5.5.1 Overview
      • 7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
    • 7.5.6 Others
      • 7.5.6.1 Overview
      • 7.5.6.2 Others: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
  • 7.6 Anticholinergics
    • 7.6.1 Overview
    • 7.6.2 Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.3 Solifenacin
      • 7.6.3.1 Overview
      • 7.6.3.2 Solifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.4 Oxybutynin
      • 7.6.4.1 Overview
      • 7.6.4.2 Oxybutynin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.5 Fesoterodine
      • 7.6.5.1 Overview
      • 7.6.5.2 Fesoterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.6 Darifenacin
      • 7.6.6.1 Overview
      • 7.6.6.2 Darifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.7 Tolterodine
      • 7.6.7.1 Overview
      • 7.6.7.2 Tolterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.8 Trospium
      • 7.6.8.1 Overview
      • 7.6.8.2 Trospium: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
    • 7.6.9 Other Anticholinergics
      • 7.6.9.1 Overview
      • 7.6.9.2 Other Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Intravesical Instillation
    • 7.7.1 Overview
    • 7.7.2 Intravesical Instillation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

8. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type

  • 8.1 Overview
  • 8.2 SAM Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
  • 8.3 Idiopathic Overactive Bladder
    • 8.3.1 Overview
    • 8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
  • 8.4 Neurogenic Overactive Bladder
    • 8.4.1 Overview
    • 8.4.2 Neurogenic: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)

9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis

Overview

    • 9.1.2 SAM: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
      • 9.1.2.1 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
      • 9.1.2.2 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
      • 9.1.2.3 Brazil: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
        • 9.1.2.3.1.1 Brazil: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
        • 9.1.2.3.1.2 Brazil Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
      • 9.1.2.4 Brazil: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
    • 9.1.3 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
      • 9.1.3.1 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
        • 9.1.3.1.1 Argentina: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
        • 9.1.3.1.1.1 Argentina: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
        • 9.1.3.1.1.2 Argentina Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
        • 9.1.3.1.2 Argentina: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
      • 9.1.3.2 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
        • 9.1.3.2.1 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
        • 9.1.3.2.2 Rest of SAM: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
        • 9.1.3.2.2.1 Rest of SAM: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
        • 9.1.3.2.2.2 Rest of South & Central America Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
        • 9.1.3.2.3 Rest of SAM: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)

10. Overactive Bladder Treatment Market- Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Developments
    • 10.2.1 Overview

11. Company Profiles

  • 11.1 Astellas Pharma Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Teva Pharmaceutical Industries Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Endo Pharmaceuticals Inc.
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Hisamitsu Pharmaceutical Co., Inc.
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Medtronic Plc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Pfizer Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms